NCT05542953View on ClinicalTrials.gov

[18F]APN-1607 PET in Subjects With AD Compared to HC

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

December 25, 2023

Study Completion Date

December 25, 2023

Conditions
Alzheimer's DiseaseMild Cognitive Impairment Due to Alzheimer's DiseaseHealthy Volunteers
Interventions
DRUG

[18F]APN-1607

In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.

Trial Locations (1)

430000

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

APRINOIA Therapeutics

INDUSTRY